Drug Discovery World

 
Tags

The Healthcare Industry’s Evolving Role in Translational Research an Opportunity for Competitive Advantage

By Gregory Venters

During the 20th century, medical research has observed enormous advances in basic science discovery, highlighted by the sequencing of the human genome. However, we have not witnessed a corresponding success in the widespread application of these advances into medical practice more...

TECHNOLOGY, bane or bonanza for the pharmaceutical industry?

By Dr Stephen Naylor, Adam W. Culbertson and Dr Stephen J. Valentine

While the adoption of new technologies into the drug development process has often been seen as a panacea this article argues that, without a true understanding of the complexities how can we expect it to be the bonanza to the pharmaceutical industry and the cure for all its woes? more...

Prediction v Attrition

By Professor Malcolm Young

A substantial number of very valuable drugs have gone, or are about to go, off patent; too few good new premium drugs are coming through to market more...

LEAN SIX SIGMA its application to drug discovery

By Clare Hammond and Charles J O’Donnell

In an increasingly competitive world, the race between pharmas to get high quality candidate drugs to market is on. Contributing to this success is the discovery phase of lead optimisation. The application of Lean and Six Sigma processes have, until now, been theorised to benefit the improvement in the rate at which drugs progress through to development and improve the quality of the clinical candidates1. It is the objective of this communication to demonstrate that this is indeed possible. more...

Outsourcing for innovation takes on new meaning

By Richard Boehner

Large pharmaceutical companies are moving quickly to outsource their drug discovery operations, predominantly to lower costs. This article argues that if outsourcing is done to capture value, ie developing and preserving intellectual property as a key competitive differentiation as well as increasing productivity, then costs will fall in line accordingly. more...

Living in hard times

By Paul Branthwaite

Maintaining knowledge and experience internally is a challenge in today’s financial climate, in SMEs and in big pharma. This article provides some tips on how companies can maintain their best staff or find reliable alternative options, especially at the critical level, when downsizing is inevitable or ‘class acts’ are unavailable more...

The DEMING Approach to Quality

By John H. Van Drie

We explore the relevance to pharmaceutical research of the ideas of W. Edwards Deming, the statistician whose ideas on quality transformed the manufacturing sector of post-war Japan. more...

Building Innovative Partnerships in Neglected Disease Research

By Prof Paul Herrling

While the recent biomedical revolution has given rise to significant advances in medical treatment, many neglected diseases that are endemic in underdeveloped parts of the world remain unaddressed. more...

Repositioning's Role in Drug Discovery and Development

By Dr Louis A. Tartaglia and Dr Lee E. Babiss

The large number of drug candidate failures in recent years has been enormously costly for the pharmaceutical industry, but has also created the tremendous opportunity of repositioning these molecules into new disease areas. more...

Implementing and Operating Large, Complex Capital Projects in a Research Environment

By Dr Tim Peakman

UK Biobank is a major UK study that will recruit 500,000 volunteers aged between 40 and 69 to provide a resource to study the link between genetic factors, environment and lifestyle in the causes of health and disease. more...

SEARCH